missing translation for 'onlineSavingsMsg'
Learn More
Learn More
Invitrogen™ SIGLEC9 Monoclonal Antibody (K8)
Description
Mouse anti Human Siglec-9, Clone K8, also known as CD329, recognizes Human sialic acid-binding Ig-like lectin 9, a single pass type I membrane protein belonging to the immunoglobulin superfamily.
SIGLEC9 (Sialic acid-binding Ig-like lectin 9) is a putative adhesion molecule that mediates sialic-acid dependent binding to cells. It contains two Ig-like C2 type (immunoglobulin-like) domains and one Ig-like V-type (immunoglobulin-like) domain. It preferentially binds to alpha2, 3-or alpha2, 6-linked sialic acid. The sialic acid recognition site may be mased by cis interactions with sialic acids on the same cell surface.
Specifications
Specifications
| Antigen | SIGLEC9 |
| Applications | ELISA, Flow Cytometry, Immunoprecipitation, Western Blot, Immunocytochemistry |
| Classification | Monoclonal |
| Clone | K8 |
| Concentration | 1 mg/mL |
| Conjugate | Unconjugated |
| Formulation | PBS with 0.09% sodium azide |
| Gene | SIGLEC9 |
| Gene Accession No. | Q9Y336 |
| Gene Alias | Cd170; CD329; CDw329; FOAP-9; LOC100062855; LOC719831; MIS; mSiglec-E; Myeloid inhibitory siglec; OBBP-LIKE; Protein FOAP-9; sialic acid binding Ig like lectin 9; sialic acid binding Ig-like lectin 5; sialic acid binding Ig-like lectin 9; sialic acid binding Ig-like lectin E; sialic acid-binding Ig-like lectin 12; Sialic acid-binding Ig-like lectin 5; sialic acid-binding Ig-like lectin 9; Sialic acid-binding Ig-like lectin E; sialic acid-binding Ig-like lectin-like 1; sialic acid-binding immunoglobulin-like lectin E; Siglec; Siglec12; siglec-12; Siglec5; Siglec-5; SIGLEC9; siglec-9; Siglece; Siglec-E; Siglecl1; siglec-L1; SIGLEC-like 1; UNQ668/PRO1302 |
| Show More |
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?